X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Religare Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs RELIGARE ENT. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

RELIGARE ENT. 
   Change

Promoted by Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh , Religare Enterprises is a financial services company, offering a wide range of financial products and services targeted at retail investors, high net worth individuals and corporat... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES RELIGARE ENT. INDOCO REMEDIES/
RELIGARE ENT.
 
P/E (TTM) x 44.5 -4.8 - View Chart
P/BV x 2.8 0.3 880.9% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 INDOCO REMEDIES   RELIGARE ENT.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
RELIGARE ENT.
Mar-17
INDOCO REMEDIES/
RELIGARE ENT.
5-Yr Chart
Click to enlarge
High Rs360295 122.2%   
Low Rs249209 119.2%   
Sales per share (Unadj.) Rs119.0184.1 64.6%  
Earnings per share (Unadj.) Rs8.4-8.5 -98.3%  
Cash flow per share (Unadj.) Rs15.2-7.0 -217.7%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7134.3 52.6%  
Shares outstanding (eoy) m92.15204.83 45.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.4 187.1%   
Avg P/E ratio x36.4-29.6 -123.1%  
P/CF ratio (eoy) x20.0-36.0 -55.6%  
Price / Book Value ratio x4.31.9 229.8%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,08351,607 54.4%   
No. of employees `0006.0NA 150,900.0%   
Total wages/salary Rs m2,1676,450 33.6%   
Avg. sales/employee Rs Th1,817.09,429,400.0 0.0%   
Avg. wages/employee Rs Th359.01,612,475.0 0.0%   
Avg. net profit/employee Rs Th127.7-435,700.0 -0.0%   
INCOME DATA
Net Sales Rs m10,96837,718 29.1%  
Other income Rs m40693 5.7%   
Total revenues Rs m11,00738,410 28.7%   
Gross profit Rs m1,56521,035 7.4%  
Depreciation Rs m633310 204.3%   
Interest Rs m6218,363 0.3%   
Profit before tax Rs m9093,055 29.8%   
Minority Interest Rs m0-507 0.0%   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m0-4,419 0.0%   
Tax Rs m139-130 -106.4%   
Profit after tax Rs m771-1,743 -44.2%  
Gross profit margin %14.355.8 25.6%  
Effective tax rate %15.3-4.3 -357.3%   
Net profit margin %7.0-4.6 -152.1%  
BALANCE SHEET DATA
Current assets Rs m5,72590,534 6.3%   
Current liabilities Rs m5,45480,912 6.7%   
Net working cap to sales %2.525.5 9.7%  
Current ratio x1.01.1 93.8%  
Inventory Days Days620 83,495.5%  
Debtors Days Days7259 121.2%  
Net fixed assets Rs m5,30712,489 42.5%   
Share capital Rs m1842,048 9.0%   
"Free" reserves Rs m6,33125,469 24.9%   
Net worth Rs m6,51627,517 23.7%   
Long term debt Rs m1,32389,166 1.5%   
Total assets Rs m11,970210,378 5.7%  
Interest coverage x15.61.2 1,341.3%   
Debt to equity ratio x0.23.2 6.3%  
Sales to assets ratio x0.90.2 511.1%   
Return on assets %7.07.9 88.1%  
Return on equity %11.8-6.3 -186.8%  
Return on capital %12.414.1 87.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1413 40,764.3%   
Net fx Rs m3,366-3 -120,196.4%   
CASH FLOW
From Operations Rs m88658,706 1.5%  
From Investments Rs m-1,70623,178 -7.4%  
From Financial Activity Rs m1,316-76,960 -1.7%  
Net Cashflow Rs m4973,238 15.3%  

Share Holding

Indian Promoters % 59.2 50.9 116.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.9 1,388.9%  
FIIs % 6.0 15.3 39.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 32.9 68.1%  
Shareholders   12,805 26,518 48.3%  
Pledged promoter(s) holding % 0.0 68.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   JSW HOLDINGS  INDIABULLS FIN. SER.  STC INDIA  COX & KINGS  COMMEX TECHNOLOGY  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

RELIGARE ENT. Announces Quarterly Results (4QFY18); Net Profit Up 27.2% (Quarterly Result Update)

Jun 4, 2018 | Updated on Jun 4, 2018

For the quarter ended March 2018, RELIGARE ENT. has posted a net profit of Rs 643 m (up 27.2% YoY). Sales on the other hand came in at Rs 3 m (down 81.0% YoY). Read on for a complete analysis of RELIGARE ENT.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 16, 2018 03:03 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS